165 related articles for article (PubMed ID: 24633771)
1. Definition of the binding mode of phosphoinositide 3-kinase α-selective inhibitor A-66S through molecular dynamics simulation.
Bian X; Dong W; Zhao Y; Sun R; Kong W; Li Y
J Mol Model; 2014 Apr; 20(4):2166. PubMed ID: 24633771
[TBL] [Abstract][Full Text] [Related]
2. Characterization of molecular recognition of phosphoinositide-3-kinase α inhibitor through molecular dynamics simulation.
Li Y; Zhang J; He D; Liang Q; Wang Y
J Mol Model; 2012 May; 18(5):1907-16. PubMed ID: 21870199
[TBL] [Abstract][Full Text] [Related]
3. Molecular Dynamics Simulations to Investigate the Binding Mode of the Natural Product Liphagal with Phosphoinositide 3-Kinase α.
Gao Y; Ma Y; Yang G; Li Y
Molecules; 2016 Jun; 21(7):. PubMed ID: 27367663
[TBL] [Abstract][Full Text] [Related]
4. Quantum biochemistry description of PI3Kα enzyme bound to selective inhibitors.
Freitas de Sousa FJ; Nunes Azevedo FF; Santos de Oliveira FL; Vieira Carletti J; Freire VN; Zanatta G
J Biomol Struct Dyn; 2023 Aug; ():1-11. PubMed ID: 37632299
[TBL] [Abstract][Full Text] [Related]
5. Docking studies on isoform-specific inhibition of phosphoinositide-3-kinases.
Sabbah DA; Vennerstrom JL; Zhong H
J Chem Inf Model; 2010 Oct; 50(10):1887-98. PubMed ID: 20866085
[TBL] [Abstract][Full Text] [Related]
6. Binding selectivity studies of phosphoinositide 3-kinases using free energy calculations.
Sabbah DA; Vennerstrom JL; Zhong HA
J Chem Inf Model; 2012 Dec; 52(12):3213-24. PubMed ID: 23157418
[TBL] [Abstract][Full Text] [Related]
7. Molecular simulation of a series of benzothiazole PI3Kα inhibitors: probing the relationship between structural features, anti-tumor potency and selectivity.
Wang J; Wang F; Xiao Z; Sheng G; Li Y; Wang Y
J Mol Model; 2012 Jul; 18(7):2943-58. PubMed ID: 22139479
[TBL] [Abstract][Full Text] [Related]
8. Combining properties of different classes of PI3Kα inhibitors to understand the molecular features that confer selectivity.
Gong GQ; Kendall JD; Dickson JMJ; Rewcastle GW; Buchanan CM; Denny WA; Shepherd PR; Flanagan JU
Biochem J; 2017 Jun; 474(13):2261-2276. PubMed ID: 28526744
[TBL] [Abstract][Full Text] [Related]
9. Cryo-EM structures of PI3Kα reveal conformational changes during inhibition and activation.
Liu X; Yang S; Hart JR; Xu Y; Zou X; Zhang H; Zhou Q; Xia T; Zhang Y; Yang D; Wang MW; Vogt PK
Proc Natl Acad Sci U S A; 2021 Nov; 118(45):. PubMed ID: 34725156
[TBL] [Abstract][Full Text] [Related]
10. Definition of the binding mode of a new class of phosphoinositide 3-kinase α-selective inhibitors using in vitro mutagenesis of non-conserved amino acids and kinetic analysis.
Zheng Z; Amran SI; Zhu J; Schmidt-Kittler O; Kinzler KW; Vogelstein B; Shepherd PR; Thompson PE; Jennings IG
Biochem J; 2012 Jun; 444(3):529-35. PubMed ID: 22502592
[TBL] [Abstract][Full Text] [Related]
11. Identification of novel potential PI3Kα inhibitors for cancer therapy.
Zhang Q; Sang F; Qian J; Lyu S; Wang W; Wang Y; Li Q; Du L
J Biomol Struct Dyn; 2021 Jul; 39(10):3721-3732. PubMed ID: 32425109
[TBL] [Abstract][Full Text] [Related]
12. Molecular dynamic simulations give insight into the mechanism of binding between 2-aminothiazole inhibitors and CDK5.
Wang W; Cao X; Zhu X; Gu Y
J Mol Model; 2013 Jun; 19(6):2635-45. PubMed ID: 23525963
[TBL] [Abstract][Full Text] [Related]
13. Identification and optimisation of a 4',5-bisthiazole series of selective phosphatidylinositol-3 kinase alpha inhibitors.
Fairhurst RA; Imbach-Weese P; Gerspacher M; Caravatti G; Furet P; Zoller T; Fritsch C; Haasen D; Trappe J; Guthy DA; Arz D; Wirth J
Bioorg Med Chem Lett; 2015 Sep; 25(17):3569-74. PubMed ID: 26206504
[TBL] [Abstract][Full Text] [Related]
14. Docking Studies and Antiproliferative Activities of 6-(3-aryl-2-propenoyl)-2(3H)- benzoxazolone Derivatives as Novel Inhibitors of Phosphatidylinositol 3-Kinase (PI3Kα).
Bilginer S; Bardaweel SK; Sabbah DA; Gul HI
Anticancer Agents Med Chem; 2021; 21(6):716-724. PubMed ID: 32767959
[TBL] [Abstract][Full Text] [Related]
15. Computational Insights into the Interactions between Calmodulin and the c/nSH2 Domains of p85α Regulatory Subunit of PI3Kα: Implication for PI3Kα Activation by Calmodulin.
Ni D; Liu D; Zhang J; Lu S
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29300353
[TBL] [Abstract][Full Text] [Related]
16. DW09849, a selective phosphatidylinositol 3-kinase (PI3K) inhibitor, prevents PI3K signaling and preferentially inhibits proliferation of cells containing the oncogenic mutation p110α (H1047R).
Liu JL; Gao GR; Zhang X; Cao SF; Guo CL; Wang X; Tong LJ; Ding J; Duan WH; Meng LH
J Pharmacol Exp Ther; 2014 Mar; 348(3):432-41. PubMed ID: 24361696
[TBL] [Abstract][Full Text] [Related]
17. Exploring a non-ATP pocket for potential allosteric modulation of PI3Kα.
Gkeka P; Papafotika A; Christoforidis S; Cournia Z
J Phys Chem B; 2015 Jan; 119(3):1002-16. PubMed ID: 25299356
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of novel condensed pyrrolo[1,2-c]pyrimidines featuring morpholine moiety as PI3Kα inhibitors.
Ibrahim MA; Abou-Seri SM; Hanna MM; Abdalla MM; El Sayed NA
Eur J Med Chem; 2015 Jun; 99():1-13. PubMed ID: 26037808
[TBL] [Abstract][Full Text] [Related]
19. Design, virtual screening, molecular docking and molecular dynamics studies of novel urushiol derivatives as potential HDAC2 selective inhibitors.
Zhou H; Wang C; Ye J; Chen H; Tao R
Gene; 2017 Dec; 637():63-71. PubMed ID: 28939339
[TBL] [Abstract][Full Text] [Related]
20. Class I phospho-inositide-3-kinases (PI3Ks) isoform-specific inhibition study by the combination of docking and molecular dynamics simulation.
Han M; Zhang JZ
J Chem Inf Model; 2010 Jan; 50(1):136-45. PubMed ID: 19928754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
